Clinical study on anti-fungal drug activity against clinically isolated strains of oral Candida species

Oral Science International

Volumn 10, Issue 2, 2013, Pages 87-94

  Kamikawa, Yoshiaki ^a   Nagayama, Tomohiro ^b   Fujisaki, Junichi ^b   Hirabayashi, Daisuke ^b   Kawasaki, Kiyotsugu ^b   Hamada, Tomofumi ^b   Mori, Youichiro ^b   Kamikawa, Yasuko ^b   Mukai, Hiroshi ^a,b   Sato, Tomoaki ^b   Sugihara, Kazumasa ^a,b  

^a KAGOSHIMA UNIVERSITY HOSPITAL   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Anti fungal drug activity; Clinically isolated strains; Minimal inhibitory concentration; Oral Candida species

Indexed keywords

EID: 84878131887     PISSN: 13488643     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1348-8643(13)00006-2     Document Type: Article

References (22)

1. Pfaller M.A., Jones R.N., Doern G.V., et al. International surveillance of blood stream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group. J Clin Microbiol 1998, 36:1886-1889.
2. Messer S.A., Moet G.J., Kirby J.T., et al. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J Clin Microbiol 2009, 47:1942-1946.
3. Villanueva A., Arathoon E.G., Gotuzzo E., et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001, 33:1529-1535.
4. Villanueva A., Gotuzzo E., Arathoon E.G., et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002, 113:294-299.
5. de Wet N., Llanos-Cuentas A., Suleiman J., et al. A randomized, double blind, parallel group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV positive patients. Clin Infect Dis 2004, 39:842-849.
6. Krause D.S., Simjee A.E., van Rensburg C., et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004, 39:770-775.
7. Takakura S., Fujihara N., Saito T., et al. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother 2004, 53:283-289.
8. Yamaguchi H., Uchida K., Okuzumi K., et al. Nationwide survey of antifungal drug susceptibility of clinical fungal isolates in Japan for the Japan Antifungal Surveillance Program (JASP), 2001-2002. J Jpn Soc Clin Microbiol 2004, 14:183-193.
9. Yamaguchi H., Uchida K., Nishiyama Y., et al. Nationwide survey of antifungal drug susceptibility of clinical fungal isolates in Japan for the Japan Antifungal Surveillance Program (JASP), 2003. J Jpn Soc Clin Microbiol 2006, 16:13-22.
10. Yamaguchi H., Nishiyama Y., Uchida K., et al. Nationwide survey of antifungal drug susceptibility of clinical fungal isolates in Japan for the Japan Antifungal Surveillance Program (JASP), 2005. J Jpn Soc Clin Microbiol 2009, 19:128-141.
11. Kanbe T., Horii T., Arishima T., et al. PCR-based identification of pathogenic Candida species using primer mixes specific to Candida DNA topoisomerase II genes. Yeast 2002, 19:973-989.
12. Pappas P.G., Kauffman C.A., Andes D., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
13. Clinical and Laboratory Standards Institute: Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard-third edition M27-A3 2008, CLSI, Wayne, PA, USA.
14. Yamaguchi H. Anti fungal drug sensitivity test. Modern Media 2009, 55:309-320.
15. Sudo T., Makimura K., Kawata K., et al. Evaluation of antifungal susceptibility testing by the broth micro dilution method against Candida species: activities of 5 antifungal agents against Candida species isolated from oral candidiasis or other candidal infectious diseases and correlation of vitro data and clinical outcome of fluconazole therapy. Jpn J Chemother 1997, 45:115-122.
16. Blignaut E., Messer S., Hollis R.J., et al. Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals. Diagn Microbiol Infect Dis 2002, 44:169-174.
17. Kuriyama T., Williams D.W., Bagg J., et al. In vitro susceptibility of oral Candida to seven antifungal agents. Oral Microbiol Immunol 2005, 20:349-353.
18. Hamza O.J., Matee M.I., Moshi M.J., et al. Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis. BMC Microbiol 2008, 8:135.
19. Yamaguchi H. Epidemiology of antifungal resistance: current status and future perspective. Modern Media 2010, 56:119-138.
20. Yamaguchi H., Enomoto S., Kaku M., et al. An open randomized parallel-comparison study of itraconazole oral solution versus itraconazole capsules in treatment of patients with oropharyngeal candidiasis. Jpn J Chemother 2006, 54(S-1):18-31.
21. Otani H., Unoue K., Shiota T., et al. Pharmacological, pharmacokinetic, and clinical profile of itraconazole ore solution (ITRIZOLE Oral Solution 1%). Folia Pharmacol Jpn 2007, 130:69-76.
22. Interview Form FLORID Oral gel 2% 2011, 16. Mochida Pharmaceutical Co., Ltd.